Soft-Shell Chamber (Mild HBOT)

Reviewed by: HBOT Hub Research Desk  ·  Last updated: October 2026

Overview

Soft-shell hyperbaric chambers (also called "mild HBOT" or mHBOT chambers) are fabric-walled portable units that pressurise to approximately 1.3 ATA using ambient air plus supplemental oxygen (typically 85–95% O₂ via concentrator). They are FDA-cleared only for acute mountain sickness, not for the broader UHMS indications list. Clinical efficacy at 1.3 ATA remains debated.

Soft-shell chambers emerged in the 1990s as portable units for high-altitude climbing, where supplemental atmospheric pressure can treat altitude sickness in the field. The design uses a flexible, airtight fabric envelope (typically urethane-coated nylon) with zipper entry, pressurised by an electric blower drawing ambient air. A separate oxygen concentrator feeds supplemental O₂ into the chamber or via a mask inside.

Over the past two decades a large consumer market has developed for home and wellness use. Marketing claims commonly extend well beyond the FDA clearance to include traumatic brain injury, autism, long COVID, anti-ageing, and sports recovery. The clinical evidence base at 1.3 ATA for these indications is substantially weaker than at the 2.0+ ATA pressures used in Efrati Lab trials and most published neurological HBOT research.

The pharmacokinetic reality: at 1.3 ATA breathing ~95% oxygen, dissolved plasma oxygen (PaO₂) is substantially lower than at the clinical 2.0 ATA / 100% O₂ standard. The physiological driver of HBOT efficacy — elevated arterial oxygen tension — is weaker. Whether this is enough to produce clinically meaningful effects for most off-label indications remains debated in the hyperbaric medical community.

How It Works

The chamber is pressurised by an air blower to approximately 1.3 ATA (~4.4 psi above atmospheric). An oxygen concentrator feeds 85–95% oxygen either into the chamber environment or via a mask worn inside the chamber. The user zips themselves into the chamber or has an operator seal them in from outside. The relatively low pressure differential compared with clinical hard-shell chambers makes construction simpler and cheaper.

Specifications

Clinical Uses

• Altitude sickness (FDA-cleared) — field use at high elevation.
• General wellness and recovery (off-label) — the largest consumer use case.
• Experimental neurological protocols (off-label) — autism, long COVID, TBI research at 1.3 ATA.
• Sports recovery (off-label) — limited RCT evidence.

Patient Experience

Users enter the fabric chamber through a zipper opening and lie down on a padded floor. The chamber is enclosed but not confining — most adults can sit up partially inside. The experience is generally comfortable; ear equalisation during the slow compression is straightforward. Noise from the air blower is a background hum. Sessions typically run 60–90 minutes.

Pros & Cons

Advantages

• Portable, home-usable, low capital cost ($5K–$20K).
• Simple operation; no certified staff required.
• Suitable for altitude sickness (FDA-cleared indication).
• Low barotrauma risk at 1.3 ATA.
• Non-claustrophobic for most users.

Limitations

• FDA-cleared only for altitude sickness; all other use is off-label.
• Clinical efficacy at 1.3 ATA for most indications is debated.
• Not suitable for UHMS-approved emergency indications.
• Marketing claims often outrun the clinical evidence.
• Oxygen concentrator may limit achievable FiO₂ (85–95% rather than 100%).

Cost & Access

Soft-shell chambers range $5,000–$20,000 depending on size, concentrator capacity, and manufacturer. Operating costs are minimal — electricity for the blower and concentrator, periodic replacement of filters and seals. No insurance reimbursement applies to home soft-shell use.

Key References

• Rossignol DA et al. (2009) — Autism RCT at 1.3 ATA; follow-up trials showed inconsistent results.
• Harch PG et al. (2017) — Veterans with post-concussion syndrome at 1.5 ATA, Med Gas Res.
• FDA 510(k) clearances — altitude sickness only; see FDA device database.
• UHMS position statements on mild HBOT marketing claims.

Research disclaimer: This reference is for educational purposes only. HBOT is a regulated medical treatment that must be administered under appropriate professional supervision. Always consult a qualified physician before considering hyperbaric therapy. Information reflects published research and regulatory guidance available at the time of review.